Cancer Policy FDA issues draft guidance on accelerating development of individualized therapies for ultra-rare diseases February 27, 2026Vol.52 No.08
Drugs & Targets FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer February 27, 2026Vol.52 No.08
Drugs & Targets FDA approves Hernexeos as an initial treatment for HER2-mutant advanced NSCLC February 27, 2026Vol.52 No.08
Cancer Policy At Friends meeting, Pazdur, Woodcock lament FDA’s failure to protect the agency staff from political interference, warn of “lasting implications” February 20, 2026Vol.52 No.07By Jacquelyn Cobb and Claire Marie Porter
Drugs & Targets FDA grants Breakthrough Therapy designation to Rybrevant Faspro in advanced head-and-neck cancer February 20, 2026Vol.52 No.07
Regulatory News CBER Director Vinay Prasad sidelined staff to jettison Moderna’s mRNA flu shot February 13, 2026Vol.52 No.06By Claire Marie Porter
Cancer Policy FDA approves labeling changes to menopausal hormone therapy products February 13, 2026Vol.52 No.06By Claire Marie Porter
Drugs & Targets FDA approves pembrolizumab with paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma February 13, 2026Vol.52 No.06
